Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING3
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| QUINTESSENTIAL NCT06297226 |
P2 | Recruiting | Multiple Myeloma | 230 | 2026-07-31 (-2 mo) |
| BMS-986393 NCT06615479 |
P3 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 440 | 2027-12-30 |
| Rituximab NCT07015242 |
P2 | Recruiting | Lymphoma | 65 | 2028-01-09 |
| CC-97540 NCT07015983 |
P2 | Active, not recruiting | Lupus Erythematosus, Systemic; Lupus Nephritis | 89 | 2028-05-17 |
| Breakfree-SSc NCT07335562 |
P3 | Not yet recruiting | Systemic Sclerosis | 92 | 2028-11-14 |
| BMS-986353 NCT07603557 |
P2 | Not yet recruiting | Chronic Immune Thrombocytopenia; Autoimmune Hemolytic Anemia | 52 | 2030-05-06 |